Accuray | ARAY - Cash And Equivalent


Accuray reported $63.34M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Accuray USD 63.34M 5.93M Sep/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 64.91M 8.52M Dec/2025
AtriCure USD 167.43M 19.56M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Hologic USD 2.17B 208.5M Dec/2025
Inogen USD 106.48M 2.79M Sep/2025
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Orthofix International USD 82.02M 19.16M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Trinity Biotech USD 1.34M 3.83M Sep/2025